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ABSTRACT
Mutations in STAT3 have recently been shown to cause autoimmune diseases 
through increased lymphoproliferation. We describe a novel Pro471Arg STAT3 
mutation in a patient with multiple autoimmune diseases, causing hyperactivation 
of the Th17 pathway. We show that IL-17 production by primary T cells was enhanced 
and could not be further increased by IL-6, while IL-10 reduced Th17 cell numbers. 
Moreover, specific inhibition of STAT3 activation resulted in diminished IL-17 
production. We show that the Pro471Arg STAT3 mutation yields both increased levels 
of IgA and IgG, probably due to high IL-21 levels. When remission was reached 
through medical intervention, IL-17 levels normalized and the clinical symptoms 
improved, supporting the idea that STAT3 gain-of-function mutations can cause 
hyperactivation of the Th17 pathway and thereby contribute to autoimmunity.
INTRODUCTION
Three recently published studies show that STAT3 
mutations can underlie autoimmune pathology [1-3]. 
Although these studies provide pathophysiological 
explanations as causes for the disease phenotype for 
several STAT3 mutations, the disease mechanisms caused 
by STAT3 mutations are not yet fully understood. STAT3 
has a role in the development of Th17 cells, which have 
been associated with several autoimmune diseases [4]. 
We here provide experimental immunological support 
in an exploratory study that increased Th17 activity can 
contribute to autoimmune pathology in patients with 
STAT3 mutations. 
RESULTS
A 17 year old female was referred for immune-
diagnostics because of multi-organ autoimmune 
disease that was present since early childhood. Immune 
dysregulation polyendocrinopathy enteropathy X-linked 
syndrome (IPEX) or IPEX-like syndrome were excluded 
by showing normal regulatory T cell (Treg) number and 
function (Supplemental Figure 1A, Supplemental patient 
description and Supplemental Tables 1 & 2). Screening 
of primary immunodeficiency related genes [5] showed 
a de novo heterozygous mutation in STAT3 (c.1412C>G 
p.(Pro471Arg), NM_139276.2) with potential pathological 
consequences (see Supplemental Figure 1B & 1C). The 
patient and her parents gave written informed consent for 
this study and blood was sampled during active disease 
and remission on Rapamycin treatment.
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Considering that IL-6 mediated STAT3 activation 
drives Th17 cell development [6] we tested components 
of this pathway in blood plasma and peripheral blood 
mononuclear cells. First, we explored circulating 
cytokines involved in the Th17 pathway by multiplex 
analysis of plasma obtained during active disease. IL-6, 
IL-17 and IL-21 were elevated in the patient compared 
to healthy donors (Figure 1A). In accordance with this, 
PMA/ionomycin activated PBMC of the patient showed 
increased numbers of IL-17 producing cells and increased 
RORγt expression within the CD4+ T cell compartment 
(Figure 1B). In contrast, IL-21 and IL-6 production 
by PBMC was reduced, possibly as a compensatory 
mechanism for already high plasma levels (Figure 1C). To 
further assess the nature of this elevated Th17 cell activity 
we cultured PBMC with increasing concentrations of IL-6. 
The number of Th17 cells was already markedly elevated 
in the patient cell culture, irrespective of IL-6 stimulation 
(Figure 1D). Addition of IL-6 did not result in more Th17 
cells, but showed a dose-dependent increase of IL-17 in 
the culture supernatants of both the healthy donors and 
patient. In contrast, STAT3 activating cytokine IL-23 
Figure 1: STAT3 Pro471Arg mutation causes hyperactive Th17 pathway and aberrant B cell phenotype. A. Blood 
plasma levels of IL-6, IL-17 and IL-21. B. IL-6, IL-17 and IL-21 production by ex vivo PMA/Ionomycin activated PBMC. C. Percentage 
of circulating IL-17+ CD4+ T cells. D. Increasing concentrations of IL-6 were added to PBMC cultures with plate bound anti-CD3 (‘-’); 
the intracellular expression of IL-17 and RORγt in CD4+ T cells was measured by flow cytometry (left) and the amount of IL-17 produced 
was determined in the supernatant after four days of culture (right). E. F. B cell phenotype; percentage of circulating plasmablasts (E) and 
IgA and IgG expression (F). G. Increasing concentrations of IL-21 were added to PBMC cultures with plate bound anti-CD3 (‘-’); surface 
expression of IgA (left) and IgG (right) was measured by flow cytometry (n = 3). Error bars represent SEM.
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did not have an IL-17 inducing effect on patient cells 
(not shown). These results show a contribution of the 
Pro471Arg STAT3 mutation to a persistent hyperactivation 
of the Th17 response independent of IL-6 signaling. 
Next to the aberrant T cell phenotype we observed 
B cell abnormalities in the patient, characterized by an 
increased presence of plasmablasts and elevated IgA 
and IgG surface expression ex vivo (Figure 1E-1F). This 
observation correlated with elevated concentrations of IgA 
and IgG in patient plasma as compared to healthy donor 
values (see Supplemental Figure 2). It is well known 
that B cell class switching, plasma cell formation and 
immunoglobulin production depend amongst others on 
IL-21 [7] which is elevated in our patient. To investigate 
whether Th17 cell effector cytokines could account for 
the observed B cell abnormalities, we cultured healthy 
donor PBMC with IL-17 and IL-21. IL-21 caused a dose-
dependent increase of class switched memory B cells and 
surface IgA and IgG expression (Figure 1G), as has been 
shown before [8]. IL-17 had no effect on B cell maturation 
and immunoglobulin expression (data not shown). Thus 
the STAT3 dependent high IL-21 levels observed in 
the patient during active disease may contribute to the 
hypergammaglobulinemia phenotype of the patient.
Figure 2: Th17 hyperactivation can be dampened. PBMC were cultured with plate bound anti-CD3 (‘-’) with or without IL-10 
(A), tocilizumab (B) or S3i-201 (C) for 4 days; the percentage of IL-17+ CD4+ T cells was measured by flow cytometry (upper panel) and 
the amount of IL-17 produced in the supernatant was determined by multiplex immunoassay (lower panel). D. Percentage of IL-17+ CD4+ 
T cells in the patient during and after treatment with Rapamycin (HC and -Rapa same data as Figure 1C) E. MFI of ex vivo pY705 STAT3 
in total T cells. F. ∆MFI (relative to HC with anti-CD3 only) of pY705 STAT3 after 4 day culture as described above (IL-10: 10 µg/mL). 
Negative values indicate decrease in MFI. Error bars represent SEM.
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To investigate whether the increased Th17 activity 
in the patient could be influenced by agents that are known 
to modulate the STAT3-Th17 pathway, we cultured PBMC 
with IL-10, IL-6 receptor blocking antibody tocilizumab 
and STAT3 inhibitor S3i-201. Increasing concentrations of 
IL-10 did not clearly affect healthy donor Th17 cells, but 
in patient cell cultures the number of Th17 cells and the 
amount of IL-17 produced were decreased (Figure 2A). 
Tocilizumab reduced the Th17 activity in healthy donors 
and the patient (Figure 2B), whereas S3i-201 did not have 
an effect on Th17 numbers, but only reduced the IL-17 
production (Figure 2C). We tested the Th17 response 
again when the patient showed reduced disease activity 
during treatment with Rapamycin. Indeed, concomitant 
with an increase in Treg numbers (not shown), Rapamycin 
treatment caused a reduction in the number of IL-17 
producing T cells after PMA/Ionomycin stimulation 
(Figure 2D). These results indicate that even though 
Th17 activity is markedly increased in the patient, it can 
be dampened by (in)direct inhibition of the STAT3-Th17 
axis, in vitro as well as in vivo.
To formally address whether an altered 
phosphorylation state of the STAT3 protein may 
contribute to the patient’s phenotype, we analyzed the 
phosphorylation of the tyrosine residue 705 (pY705) of 
STAT3 in fresh cells and upon culture with anti-CD3 
with or without IL-10, tocilizumab or S3i-201. The 
Y705 phosphorylation status was comparable between 
the patient and healthy donor cells (Figure 2E). After 
4-day culture, STAT3 Y705 phosphorylation was even 
lower in patient cells. Addition of tocilizumab or S3i-
201 did reduce the phosphorylation in both healthy 
donor and patient cells (Figure 2F). Thus, constitutive 
phosphorylation of the STAT3 Y705  tyrosine does not 
explain the observed phenotype.
DISCUSSION
In summary, we here show in primary patient 
material that the Pro471Arg STAT3 mutation correlates 
with a highly activated Th17 pathway and contributes 
to autoimmune pathology and activated B cells. The 
elevated IL-21 levels (which could be produced by 
Th17 cells but also by NKT and T follicular helper 
cells) as found in the patient plasma likely supports class 
switching and could thereby contribute to the observed 
hypergammaglobulinemia. The clinical characteristics 
of the patient described here and the patients described 
elsewhere [1-3] clearly diverge from hyper-IgE syndromes 
that are associated with STAT3 mutations [9]. The 
diversity in clinical manifestations of STAT3 mutations 
suggests that mutations in this gene might underlie 
more autoimmune disorders, specifically when disease 
onset occurs at early age. While we concede that the 
Th17 pathway may not account for all these phenotypes 
and most data are obtained from a limited number of 
samples, the immunological data provided are suggestive 
of the Th17 pathway contributing to more autoimmune 
disorders than currently recognized. We therefore suggest 
that sequencing of STAT3 should be considered in more 
patients with severe autoimmunity, and specified treatment 
options focusing on the Th17 pathway like tocilizumab 
should be further explored for these patients.
MATERIALS AND METHODS
Patient material was collected once during active 
disease and once during disease remission on Rapamycin 
treatment. Plasma and peripheral blood mononuclear 
cells (PBMC) of patient and healthy controls were 
stored at -150°C for later use in experiments. Cytokine 
concentrations were measured in plasma and culture 
supernatants by multiplex immunoassay as described 
elsewhere [10]. PBMC were activated with 20 ng/ml 
phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml 
ionomycin for 4 hours to measure cytokine production in 
supernatant or by 1 µg/ml anti-CD3 (okt3, eBioscience, 
San Diego, USA) and cultured for four days with or 
without recombinant IL-6 (Miltenyi, Bergisch Gladbach, 
Germany) or IL-10 (BD Bioscience, San Jose, USA). 
Monensin (Golgistop, BD Bioscience) was added during 
the last 3.5 h PMA/Ionomycin stimulation for flow 
cytometric analysis of intracellular cytokine expression. 
STAT3 activity was inhibited by addition of 50 µM S3I-
201 (Santa Cruz Biotechnology, Heidelberg, Germany) 
and phosphorylation investigated with anti-pY705 
STAT3 (Clone 4/P-STAT3 BD Bioscience). For analysis 
of B cell differentiation, PBMC were cultured for 5 days 
with plate bound anti-CD3 and rhIL-21 (1 and 10 ng/ml; 
Immunotools) or rhIL-17 (1 and 10 ng/ml; Immunotools). 
Suppression assays were conducted with Treg inspector 
beads (Miltenyi) and CD4+CD25+CD127- sorted Treg.
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IL: Interleukin
IPEX: Immune dysregulation polyendocrinopathy 
enteropathy X-linked
PBMC: Peripheral blood mononuclear cells
PMA: Phorbol 12-myristate 13-acetate
RORγT: RAR related orphan receptor gamma T
STAT3: Signal transducer and activator of 
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Teff: T effector cell
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